Publication:
Development of biological tools to assess the role of TMPRSS4 and identification of novel tumor types with high expression of this prometastatic protein

Thumbnail Image
Files
Villalba-32-929-940-2017.pdf(11.3 MB)
Date
2017
relationships.isAuthorOfPublication
relationships.isSecondaryAuthorOf
relationships.isDirectorOf
Authors
Villalba, Maria ; Lopez, Lissett ; Redrado, Miriam ; Ruiz, Tamara ; de Aberasturi, Arrate L. ; de la Roja, Nuria ; Garcia, David ; Exposito, Francisco ; de Andrea, Carlos ; Álvarez Fernández, Emilio ; Montuenga, Luis ; Rueda, Paloma ; Rodriguez, Maria Jose ; Calvo, Alfonso
item.page.secondaryauthor
item.page.director
Publisher
Universidad de Murcia. Departamento de Biología Celular e Histología
publication.page.editor
publication.page.department
DOI
DOI: 10.14670/HH-11-857
item.page.type
info:eu-repo/semantics/article
Description
Abstract
Metastatic spread is responsible for the majority of cancer deaths and identification of metastasisrelated therapeutic targets is compulsory. TMPRSS4 is a pro-metastatic druggable transmembrane type II serine protease whose expression has been associated with the development of several cancer types and poor prognosis. To study the role and expression of this protease in cancer, we have developed molecular tools (active recombinant proteins and a polyclonal antibody) that can be used for diagnostic purposes and for testing anti-TMPRSS4 drugs. In addition, we have evaluated TMPRSS4 protein expression in several cancer tissue microarrays (TMAs). Full length and truncated TMPRSS4 recombinant proteins maintained the catalytic activity in two different expression systems (baculovirus and E. coli). Sensitivity of the rabbit polyclonal antisera against TMPRSS4 (ING-pAb) outperformed the antibody most commonly used in clinical settings. Analysis by immunohistochemistry in the different TMAs identified a subset of adenocarcinomas, squamous carcinomas, large cell carcinomas and carcinoids of the lung, in which TMPRSS4 expression may define aggressive tumors. In conclusion, our biological tools will help the characterization of TMPRSS4 activity and protein expression, as well as the evaluation of anti-TMPRSS4 drugs. Future studies should determine the clinical value of assessing TMPRSS4 levels in different types of lung cancer.
publication.page.subject
TMPRSS4 , Recombinant proteins , Squamous lung carcinomas
Citation
Histology and Histopathology, Vol.32, nº9, (2017)
URI
http://hdl.handle.net/10201/117567
item.page.embargo
Collections
Histology and histopathology Vol.32, nº9 (2017)
Ir a Estadísticas